Home Cart Sign in  
Chemical Structure| 935666-88-9 Chemical Structure| 935666-88-9

Structure of AZD-1480
CAS No.: 935666-88-9

Chemical Structure| 935666-88-9

AZD-1480

CAS No.: 935666-88-9

AZD-1480 is a JAK1 and JAK2 inhibitor with IC50 values of 1.3 nM and 0.4 nM, respectively.

4.5 *For Research Use Only !

Cat. No.: A209618 Purity: 98+%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łÍʶÊÊ Inquiry Inquiry
5mg łÍó¶ÊÊ Inquiry Inquiry
10mg łďď¶ÊÊ Inquiry Inquiry
50mg łÇî˶ÊÊ Inquiry Inquiry
100mg ł§Íî¶ÊÊ Inquiry Inquiry
250mg łóď˶ÊÊ Inquiry Inquiry
1g łËÿď§¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • 1mg

    łÍʶÊÊ

  • 5mg

    łÍó¶ÊÊ

  • 10mg

    łďď¶ÊÊ

  • 50mg

    łÇî˶ÊÊ

  • 100mg

    ł§Íî¶ÊÊ

  • 250mg

    łóď˶ÊÊ

  • 1g

    łËÿď§¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AZD-1480

CAS No. :935666-88-9
Formula : C14H14ClFN8
M.W : 348.77
SMILES Code : CC1=CC(NC2=NC(N[C@H](C3=NC=C(F)C=N3)C)=NC=C2Cl)=NN1
MDL No. :MFCD16038904
InChI Key :PDOQBOJDRPLBQU-QMMMGPOBSA-N
Pubchem ID :16659841

Safety of AZD-1480

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of AZD-1480

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • JAK2

    JAK2, IC50:0.26 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
PSCs 2 μM 48 h AZD-1480 reduced IL6 expression induced by hypoxia, while rescuing hypoxia-mediated repression of αSMA PMC10658995
HNSCC cell lines 0.9 to 4 μM 72 h AZD1480 inhibited HNSCC cell line proliferation and reduced pSTAT3 Tyr705 expression PMC4372647
RCAS high-grade cell line 1.0 μM 48 and 72 h Measure cell growth, AZD1480 had no significant effect on cell proliferation PMC5769921
U87 and U251 cells 0.5 and 1.0 μM 24, 48, and 72 h Measure cell growth, AZD1480 had no significant effect on cell proliferation PMC5769921
Mouse endothelial cells 0.5 μM 2 h AZD1480 inhibited STAT3 phosphorylation induced by Renca tumor conditioned medium in mouse endothelial cells. PMC3206173
DU145 cells 800 nM 72 h AZD1480 suppressed IL-6-induced migration and heterotypic adhesion of DU145 cells, but did not significantly affect cell viability. PMC4013199
CWR22Rv1 cells 800 nM 72 h AZD1480 suppressed IL-6-induced migration and heterotypic adhesion of CWR22Rv1 cells. PMC4013199
U251-MG 1 µM 30 min to 16 h AZD1480 inhibited STAT-3 and JAK2 phosphorylation in U251-MG cells, leading to decreased cell proliferation and induction of apoptosis. PMC3237864
U87-MG 1 µM 30 min to 16 h AZD1480 inhibited STAT-3 and JAK2 phosphorylation in U87-MG cells, leading to decreased cell proliferation and induction of apoptosis. PMC3237864
4C8 1 µM 30 min to 16 h AZD1480 inhibited STAT-3 and JAK2 phosphorylation in 4C8 cells, leading to decreased cell proliferation and induction of apoptosis. PMC3237864
GBM cells 0.1, 0.5, 1, 2 μM 5 days To evaluate the effect of STAT3 inhibitors on GBM cell viability, results showed that STAT3-high cells were more sensitive to AZD1480, with significantly reduced viability. PMC6689009
GBM cells 0.1, 0.5, 1, 2 μM 5 days To evaluate the effect of STAT3 inhibitors on GBM cell viability, results showed that STAT3-low cells were not sensitive to AZD1480, with minimal changes in viability. PMC6689009
UMSCC-1 0.9 to 4 μM 72 h To evaluate the effect of AZD-1480 on HNSCC cell proliferation, results showed that AZD-1480 inhibited cell proliferation and reduced pSTAT3 Tyr705 expression PMC4372647
HN5 0.9 to 4 μM 72 h To evaluate the effect of AZD-1480 on HNSCC cell proliferation, results showed that AZD-1480 inhibited cell proliferation and reduced pSTAT3 Tyr705 expression PMC4372647
Cal33 0.9 to 4 μM 72 h To evaluate the effect of AZD-1480 on HNSCC cell proliferation, results showed that AZD-1480 inhibited cell proliferation and reduced pSTAT3 Tyr705 expression PMC4372647

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice patient-derived xenograft models oral 30 mg/kg twice daily for 13 to 15 days AZD1480 significantly slowed tumor growth and reduced pSTAT3 Tyr705 expression PMC4372647
mice RCAS murine glioma model oral 60 mg/kg once daily, 5 days a week, for 3 weeks AZD1480 blocks recruitment of CD11b+ cells to the tumor, reduces tumor burden, and prolongs survival PMC5769921
Mice Renca tumor model Oral 50 mg/kg Once daily for 21 days AZD1480 significantly inhibited Renca tumor growth and reduced myeloid cell infiltration in the tumor microenvironment. PMC3206173
nude mice prostate cancer metastasis model oral 50 mg/kg daily for 8 weeks AZD1480 significantly suppressed IL-6-driven prostate cancer metastasis in nude mice. PMC4013199
Nude mice Human GBM xenograft model Intraperitoneal injection 30 mg/kg Twice daily for 3 weeks AZD1480 significantly inhibited the growth of subcutaneous tumors and increased the survival of mice bearing intracranial GBM tumors by inhibiting STAT-3 activity. PMC3237864
Mice Patient-derived xenograft (PDX) models Oral 30 mg/kg Twice daily, for 13 to 15 days To evaluate the antitumor efficacy of AZD-1480 on HNSCC tumor growth, results showed that AZD-1480 significantly reduced tumor volume and decreased pSTAT3 Tyr705 expression PMC4372647
Mice PANC1 subcutaneous xenograft model Oral 30 mg/kg 5 days/week for 3 weeks AZD1480 alone or in combination with gemcitabine significantly inhibited tumor growth and enhanced tumor drug delivery PMC4863449

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00910728 Primary Myelofibrosis (PMF) ... More >> Post-Polycythaemia Vera Essential Thrombocythaemia Myelofibrosis Less << Phase 1 Completed - United States, New York ... More >> Research Site New York, New York, United States United States, Texas Research Site Houston, Texas, United States France Research Site Villejuif Cedex, France Less <<
NCT01112397 Solid Malignancies Phase 1 Terminated(Decision to stop de... More >>velopment of AZD1480) Less << - United States, Colorado ... More >> Research Site Aurora, Colorado, United States United States, Michigan Research Site Detroit, Michigan, United States United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States Less <<
NCT00910728 - Completed - -
NCT01219543 Solid Tumour ... More >>Advanced Solid Malignancies Child-Pugh A to B7 Advanced Hepatocellular Carcinoma EGFR and/or ROS Mutant NSCLC Lung Metastasis Carcinoma Gastric Cancer Less << Phase 1 Terminated(Compound developmen... More >>t discontinued) Less << - Korea, Republic of ... More >> Research Site Seoul, Korea, Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.87mL

0.57mL

0.29mL

14.34mL

2.87mL

1.43mL

28.67mL

5.73mL

2.87mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories